Self-assembling protein nanoparticles in the design of vaccines

Computational and Structural Biotechnology Journal

Volumn 14, Issue , 2016, Pages 58-68

  López Sagaseta, Jacinto ^a   Malito, Enrico ^a   Rappuoli, Rino ^a   Bottomley, Matthew J ^a  

^a GSK   (Italy)

Author keywords

Ferritin; HBV; HCV; HIV; HPV; Influenza; Lumazine synthase; Malaria; Structural biology; Virus like particle (VLP)

Indexed keywords

ANTIGENS; BINDING SITES; NANOPARTICLES; PATHOGENS; PROTEINS; VACCINES; VIRUSES;

FERRITIN; INFLUENZA; LUMAZINE SYNTHASE; MALARIA; STRUCTURAL BIOLOGY; VIRUS-LIKE PARTICLES;

DISEASES;

ANTIGEN; NANOPARTICLE; POLYPEPTIDE; VACCINE; VIRUS PROTEIN;

BINDING SITE; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; GEOMETRY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNITY; IMMUNOGENICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN SUBUNIT; REVIEW; VIRUS LIKE AGENT;

EID: 84961683860     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2015.11.001     Document Type: Short Survey

References (134)

1. J. Ehreth The global value of vaccination Vaccine 21 2003 596 600
2. R. Rappuoli, M. Pizza, G. Del Giudice, and E. De Gregorio Vaccines, new opportunities for a new society Proc Natl Acad Sci U S A 111 2014 12288 12293
3. K.C. Klontz, and N. Singh Treatment of drug-resistant Shigella infections Expert Rev Anti Infect Ther 13 2015 69 80
4. S. Plotkin History of vaccination Proc Natl Acad Sci U S A 111 2014 12283 12287
5. W.N. Takahashi, and M. Ishii An abnormal protein associated with tobacco mosaic virus infection Nature 169 1952 419 420
6. J.L. Gerin, P.V. Holland, and R.H. Purcell Australia antigen: large-scale purification from human serum and biochemical studies of its proteins J Virol 7 1971 569 576
7. M.R. Hilleman Vaccines in historic evolution and perspective: a narrative of vaccine discoveries Vaccine 18 2000 1436 1447
8. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat Rev Immunol 10 2010 787 796
9. L.A. Lee, and Q. Wang Adaptations of nanoscale viruses and other protein cages for medical applications Nanomedicine 2 2006 137 149
10. S.M. Kang, P. Pushko, R.A. Bright, G. Smith, and R.W. Compans Influenza virus-like particles as pandemic vaccines Curr Top Microbiol Immunol 333 2009 269 289
11. M.O. Oyewumi, A. Kumar, and Z. Cui Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses Expert Rev Vaccines 9 2010 1095 1107
12. J.R. Caston, and J.L. Carrascosa The basic architecture of viruses Subcell Biochem 68 2013 53 75
13. D.S. Goodsell, and A.J. Olson Structural symmetry and protein function Annu Rev Biophys Biomol Struct 29 2000 105 153
14. R.P. Feynman There's plenty of room at the bottom Eng Sci 1960 22 36
15. K. Rajagopal, and J.P. Schneider Self-assembling peptides and proteins for nanotechnological applications Curr Opin Struct Biol 14 2004 480 486
16. K.E. Drexler Molecular engineering: An approach to the development of general capabilities for molecular manipulation Proc Natl Acad Sci U S A 78 1981 5275 5278
17. N.P. King, and Y.T. Lai Practical approaches to designing novel protein assemblies Curr Opin Struct Biol 23 2013 632 638
18. V.F. de la Cruz, A.A. Lal, and T.F. McCutchan Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage J Biol Chem 263 1988 4318 4322
19. N.R. Burns, H.R. Saibil, N.S. White, J.F. Pardon, P.A. Timmins, S.M. Richardson, and et al. Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles EMBO J 11 1992 1155 1164
20. B.E. Clarke, S.E. Newton, A.R. Carroll, M.J. Francis, G. Appleyard, A.D. Syred, and et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein Nature 330 1987 381 384
21. F. Delpeyroux, N. Chenciner, A. Lim, Y. Malpiece, B. Blondel, R. Crainic, and et al. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles Science 233 1986 472 475
22. A.S. Belyaev, and P. Roy Presentation of hepatitis B virus preS2 epitope on bluetongue virus core-like particles Virology 190 1992 840 844
23. C.S. Brown, S. Welling-Wester, M. Feijlbrief, J.W. Van Lent, and W.J. Spaan Chimeric parvovirus B19 capsids for the presentation of foreign epitopes Virology 198 1994 477 488
24. D.J. Hwang, I.M. Roberts, and T.M. Wilson Expression of tobacco mosaic virus coat protein and assembly of pseudovirus particles in Escherichia coli Proc Natl Acad Sci U S A 91 1994 9067 9071
25. T.O. Yeates, D.H. Jacobson, A. Martin, C. Wychowski, M. Girard, D.J. Filman, and et al. Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera EMBO J 10 1991 2331 2341
26. S.D. London, A.L. Schmaljohn, J.M. Dalrymple, and C.M. Rice Infectious enveloped RNA virus antigenic chimeras Proc Natl Acad Sci U S A 89 1992 207 211
27. S.M. Garland, M. Hernandez-Avila, C.M. Wheeler, G. Perez, D.M. Harper, S. Leodolter, and et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 356 2007 1928 1943
28. J. Paavonen, D. Jenkins, F.X. Bosch, P. Naud, J. Salmeron, C.M. Wheeler, and et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2007 2161 2170
29. E. Malito, A. Carfi, and M.J. Bottomley Protein Crystallography in Vaccine Research and Development Int J Mol Sci 16 2015 13106 13140
30. P.R. Dormitzer, G. Grandi, and R. Rappuoli Structural vaccinology starts to deliver Nat Rev Microbiol 10 2012 807 813
31. D.J. Irvine, M.C. Hanson, K. Rakhra, and T. Tokatlian Synthetic Nanoparticles for Vaccines and Immunotherapy Chem Rev 115 19 2015 11109 11146
32. J.D. Smith, L.D. Morton, and B.D. Ulery Nanoparticles as synthetic vaccines Curr Opin Biotechnol 34 2015 217 224
33. M. Singh, A. Chakrapani, and D. O'Hagan Nanoparticles and microparticles as vaccine-delivery systems Expert Rev Vaccines 6 2007 797 808
34. F. Fernandes, A.P. Teixeira, N. Carinhas, M.J. Carrondo, and P.M. Alves Insect cells as a production platform of complex virus-like particles Expert Rev Vaccines 12 2013 225 236
35. A.F. Rodrigues, H.R. Soares, M.R. Guerreiro, P.M. Alves, and A.S. Coroadinha Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology Biotechnol J 10 9 2015 1329 1344
36. D.G. Kleid, D. Yansura, B. Small, D. Dowbenko, D.M. Moore, M.J. Grubman, and et al. Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine Science 214 1981 1125 1129
37. P. Valenzuela, A. Medina, W.J. Rutter, G. Ammerer, and B.D. Hall Synthesis and assembly of hepatitis B virus surface antigen particles in yeast Nature 298 1982 347 350
38. W.J. McAleer, E.B. Buynak, R.Z. Maigetter, D.E. Wampler, W.J. Miller, and M.R. Hilleman Human hepatitis B vaccine from recombinant yeast Nature 307 1984 178 180
39. G.M. Keating, and S. Noble Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B Drugs 63 2003 1021 1051
40. D.R. Lowy, and J.T. Schiller Prophylactic human papillomavirus vaccines J Clin Invest 116 2006 1167 1173
41. D.M. Salunke, D.L. Caspar, and R.L. Garcea Self-assembly of purified polyomavirus capsid protein VP1 Cell 46 1986 895 904
42. S. Kajigaya, H. Fujii, A. Field, S. Anderson, S. Rosenfeld, L.J. Anderson, and et al. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions Proc Natl Acad Sci U S A 88 1991 4646 4650
43. R. Kirnbauer, F. Booy, N. Cheng, D.R. Lowy, and J.T. Schiller Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic Proc Natl Acad Sci U S A 89 1992 12180 12184
44. R.C. Rose, W. Bonnez, R.C. Reichman, and R.L. Garcea Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles J Virol 67 1993 1936 1944
45. B. Bishop, J. Dasgupta, M. Klein, R.L. Garcea, N.D. Christensen, R. Zhao, and et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies J Biol Chem 282 2007 31803 31811
46. G. Cardone, A.L. Moyer, N. Cheng, C.D. Thompson, I. Dvoretzky, D.R. Lowy, and et al. Maturation of the human papillomavirus 16 capsid MBio 5 2014 e01104 e01114
47. J. Guan, S.M. Bywaters, S.A. Brendle, H. Lee, R.E. Ashley, A.M. Makhov, and et al. Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization Virology 483 2015 253 263
48. H. Lee, S.A. Brendle, S.M. Bywaters, J. Guan, R.E. Ashley, J.D. Yoder, and et al. A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment J Virol 89 2015 1428 1438
49. D.R. Lowy, D. Solomon, A. Hildesheim, J.T. Schiller, and M. Schiffman Human papillomavirus infection and the primary and secondary prevention of cervical cancer Cancer 113 2008 1980 1993
50. M. Sabara, M. Parker, P. Aha, C. Cosco, E. Gibbons, S. Parsons, and et al. Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins J Virol 65 1991 6994 6997
51. T. Urakawa, M. Ferguson, P.D. Minor, J. Cooper, M. Sullivan, J.W. Almond, and et al. Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector J Gen Virol 70 Pt 6 1989 1453 1463
52. D.R. Thomsen, L.L. Roof, and F.L. Homa Assembly of herpes simplex virus (HSV) intermediate capsids in insect cells infected with recombinant baculoviruses expressing HSV capsid proteins J Virol 68 1994 2442 2457
53. J.I. Casal, P. Rueda, and A. Hurtado Parvovirus-like particles as vaccine vectors Methods 19 1999 174 186
54. B.J. Cohen, and J.E. Richmond Electron microscopy of hepatitis B core antigen synthesized in E. coli Nature 296 1982 677 679
55. B. Bottcher, S.A. Wynne, and R.A. Crowther Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy Nature 386 1997 88 91
56. R.A. Crowther, N.A. Kiselev, B. Bottcher, J.A. Berriman, G.P. Borisova, V. Ose, and et al. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy Cell 77 1994 943 950
57. M.J. Francis, G.Z. Hastings, A.L. Brown, K.G. Grace, D.J. Rowlands, F. Brown, and et al. Immunological properties of hepatitis B core antigen fusion proteins Proc Natl Acad Sci U S A 87 1990 2545 2549
58. F. Schodel, D. Peterson, J. Hughes, R. Wirtz, and D. Milich Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes J Biotechnol 44 1996 91 96
59. E.H. Nardin, G.A. Oliveira, J.M. Calvo-Calle, K. Wetzel, C. Maier, A.J. Birkett, and et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes Infect Immun 72 2004 6519 6527
60. J. Cohen, V. Nussenzweig, R. Nussenzweig, J. Vekemans, and A. Leach From the circumsporozoite protein to the RTS, S/AS candidate vaccine Hum Vaccin 6 2010 90 96
61. S.C.T.P. Rts, S.T. Agnandji, B. Lell, J.F. Fernandes, B.P. Abossolo, B.G. Methogo, and et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants N Engl J Med 367 2012 2284 2295
62. K.J. Wilby, T.T. Lau, S.E. Gilchrist, and M.H. Ensom Mosquirix (RTS, S): a novel vaccine for the prevention of Plasmodium falciparum malaria Ann Pharmacother 46 2012 384 393
63. S.C.T.P. Rts Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial Lancet 386 2015 31 45
64. P. Maurer, and M.F. Bachmann Vaccination against nicotine: an emerging therapy for tobacco dependence Expert Opin Investig Drugs 16 2007 1775 1783
65. B. Chackerian Virus-like particle based vaccines for Alzheimer disease Hum Vaccin 6 2010 926 930
66. H. Nair, D.J. Nokes, B.D. Gessner, M. Dherani, S.A. Madhi, R.J. Singleton, and et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 375 2010 1545 1555
67. R. Anderson, Y. Huang, and J.M. Langley Prospects for defined epitope vaccines for respiratory syncytial virus Future Microbiol 5 2010 585 602
68. B.E. Correia, J.T. Bates, R.J. Loomis, G. Baneyx, C. Carrico, J.G. Jardine, and et al. Proof of principle for epitope-focused vaccine design Nature 507 7491 2014 201 206
69. A. Jegerlehner, A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kundig, and et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses Vaccine 20 2002 3104 3112
70. E.V. Grgacic, and D.A. Anderson Virus-like particles: passport to immune recognition Methods 40 2006 60 65
71. T.C. Li, Y. Yamakawa, K. Suzuki, M. Tatsumi, M.A. Razak, T. Uchida, and et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus J Virol 71 1997 7207 7213
72. J. Zhang, X.F. Zhang, S.J. Huang, T. Wu, Y.M. Hu, Z.Z. Wang, and et al. Long-term efficacy of a hepatitis E vaccine N Engl J Med 372 2015 914 922
73. F.C. Zhu, J. Zhang, X.F. Zhang, C. Zhou, Z.Z. Wang, S.J. Huang, and et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial Lancet 376 2010 895 902
74. J.R. Haynes Influenza virus-like particle vaccines Expert Rev Vaccines 8 2009 435 445
75. T. Latham, and J.M. Galarza Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins J Virol 75 2001 6154 6165
76. J.M. Galarza, T. Latham, and A. Cupo Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge Viral Immunol 18 2005 244 251
77. G.E. Smith, D.C. Flyer, R. Raghunandan, Y. Liu, Z. Wei, Y. Wu, and et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus Vaccine 31 2013 4305 4313
78. Y.V. Liu, M.J. Massare, M.B. Pearce, X. Sun, J.A. Belser, T.R. Maines, and et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets Vaccine 33 2015 2152 2158
79. L.F. Fries, G.E. Smith, and G.M. Glenn A recombinant viruslike particle influenza A (H7N9) vaccine N Engl J Med 369 2013 2564 2566
80. L. Zhang, J. Lu, Y. Chen, F. Shi, H. Yu, C. Huang, and et al. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice Viruses 7 2015 4369 4384
81. L.M. Schwartzman, A.L. Cathcart, L.M. Pujanauski, L. Qi, J.C. Kash, and J.K. Taubenberger An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus MBio 6 2015 e01044
82. E. Feshchenko, D.G. Rhodes, R. Felberbaum, C. McPherson, J.A. Rininger, P. Post, and et al. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability BMC Biotechnol 12 2012 77
83. M.M. Cox, R. Izikson, P. Post, and L. Dunkle Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults Ther Adv Vaccines 3 2015 97 108
84. M.P. Azevedo, A.N. Vlasova, and L.J. Saif Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease Expert Rev Vaccines 12 2013 169 181
85. T. Li, H. Lin, Y. Zhang, M. Li, D. Wang, Y. Che, and et al. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles Vaccine 32 2014 1921 1931
86. L. Buonaguro, M. Tagliamonte, M.L. Visciano, M.L. Tornesello, and F.M. Buonaguro Developments in virus-like particle-based vaccines for HIV Expert Rev Vaccines 12 2013 119 127
87. N. Aliabadi, B.A. Lopman, U.D. Parashar, and A.J. Hall Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations Expert Rev Vaccines 14 2015 1241 1253
88. C. Richardson, R.F. Bargatze, R. Goodwin, and P.M. Mendelman Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis Expert Rev Vaccines 12 2013 155 167
89. X. Jiang, M. Wang, D.Y. Graham, and M.K. Estes Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein J Virol 66 1992 6527 6532
90. K.J. Cho, H.J. Shin, J.H. Lee, K.J. Kim, S.S. Park, Y. Lee, and et al. The crystal structure of ferritin from Helicobacter pylori reveals unusual conformational changes for iron uptake J Mol Biol 390 2009 83 98
91. T. Granier, B. Langlois d'Estaintot, B. Gallois, J.M. Chevalier, G. Precigoux, P. Santambrogio, and et al. Structural description of the active sites of mouse L-chain ferritin at 1.2 A resolution J Biol Inorg Chem 8 2003 105 111
92. D.M. Lawson, P.J. Artymiuk, S.J. Yewdall, J.M. Smith, J.C. Livingstone, A. Treffry, and et al. Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts Nature 349 1991 541 544
93. M. Kanekiyo, C.J. Wei, H.M. Yassine, P.M. McTamney, J.C. Boyington, J.R. Whittle, and et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies Nature 499 7456 2013 102 106
94. H.M. Yassine, J.C. Boyington, P.M. McTamney, C.J. Wei, M. Kanekiyo, W.P. Kong, and et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection Nat Med 21 9 2015 1065 1070
95. M. Kanekiyo, W. Bu, M.G. Joyce, G. Meng, J.R. Whittle, U. Baxa, and et al. Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site Cell 162 5 2015 1090 1100
96. L. He, Y. Cheng, L. Kong, P. Azadnia, E. Giang, J. Kim, and et al. Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding Sci Rep 5 2015 12501
97. D.R. Burton Scaffolding to build a rational vaccine design strategy Proc Natl Acad Sci U S A 107 2010 17859 17860
98. T. Zhou, J. Zhu, Y. Yang, J. Gorman, G. Ofek, S. Srivatsan, and et al. Transplanting supersites of HIV-1 vulnerability PLoS One 9 2014 e99881
99. J. Jardine, J.P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, and et al. Rational HIV immunogen design to target specific germline B cell receptors Science 340 2013 711 716
100. S.E. Weber SaS Flavins and Flavoproteins Methods and Protocols, Series: Methods in Molecular Biology 2014 1146
101. X. Zhang, P.V. Konarev, M.V. Petoukhov, D.I. Svergun, L. Xing, R.H. Cheng, and et al. Multiple assembly states of lumazine synthase: a model relating catalytic function and molecular assembly J Mol Biol 362 2006 753 770
102. K. Simons, A. Helenius, K. Leonard, M. Sarvas, and M.J. Gething Formation of protein micelles from amphiphilic membrane proteins Proc Natl Acad Sci U S A 75 1978 5306 5310
103. G. Smith, R. Raghunandan, Y. Wu, Y. Liu, M. Massare, M. Nathan, and et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats PLoS One 7 2012 e50852
104. G.M. Glenn, L.F. Fries, D.N. Thomas, G. Smith, E. Kpamegan, H. Lu, and et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age J Infect Dis 2015
105. C.M. Coleman, Y.V. Liu, H. Mu, J.K. Taylor, M. Massare, D.C. Flyer, and et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice Vaccine 32 2014 3169 3174
106. S. Raman, G. Machaidze, A. Lustig, U. Aebi, and P. Burkhard Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles Nanomedicine 2 2006 95 102
107. S. Raman, G. Machaidze, A. Lustig, V. Olivieri, U. Aebi, and P. Burkhard Design of peptide nanoparticles using simple protein oligomerization domains Open Nanomedicine J 2 2009 15 26
108. T.A. Pimentel, Z. Yan, S.A. Jeffers, K.V. Holmes, R.S. Hodges, and P. Burkhard Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine Chem Biol Drug Des 73 2009 53 61
109. N. Wahome, T. Pfeiffer, I. Ambiel, Y. Yang, O.T. Keppler, V. Bosch, and et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine Chem Biol Drug Des 80 2012 349 357
110. S.A. Kaba, C. Brando, Q. Guo, C. Mittelholzer, S. Raman, D. Tropel, and et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria J Immunol 183 2009 7268 7277
111. T.O. Yeates, and J.E. Padilla Designing supramolecular protein assemblies Curr Opin Struct Biol 12 2002 464 470
112. J.E. Padilla, C. Colovos, and T.O. Yeates Nanohedra: using symmetry to design self assembling protein cages, layers, crystals, and filaments Proc Natl Acad Sci U S A 98 2001 2217 2221
113. Y.T. Lai, D. Cascio, and T.O. Yeates Structure of a 16-nm cage designed by using protein oligomers Science 336 2012 1129
114. J.C. Sinclair, K.M. Davies, C. Venien-Bryan, and M.E. Noble Generation of protein lattices by fusing proteins with matching rotational symmetry Nat Nanotechnol 6 2011 558 562
115. Y.T. Lai, E. Reading, G.L. Hura, K.L. Tsai, A. Laganowsky, F.J. Asturias, and et al. Structure of a designed protein cage that self-assembles into a highly porous cube Nat Chem 6 2014 1065 1071
116. T.O. Yeates Nanobiotechnology: protein arrays made to order Nat Nanotechnol 6 2011 541 542
117. N.P. King, W. Sheffler, M.R. Sawaya, B.S. Vollmar, J.P. Sumida, I. Andre, and et al. Computational design of self-assembling protein nanomaterials with atomic level accuracy Science 336 2012 1171 1174
118. F. DiMaio, A. Leaver-Fay, P. Bradley, D. Baker, and I. Andre Modeling symmetric macromolecular structures in Rosetta3 PLoS One 6 2011 e20450
119. B. Kuhlman, and D. Baker Native protein sequences are close to optimal for their structures Proc Natl Acad Sci U S A 97 2000 10383 10388
120. S. Cooper, F. Khatib, A. Treuille, J. Barbero, J. Lee, M. Beenen, and et al. Predicting protein structures with a multiplayer online game Nature 466 2010 756 760
121. N.P. King, J.B. Bale, W. Sheffler, D.E. McNamara, S. Gonen, T. Gonen, and et al. Accurate design of co-assembling multi-component protein nanomaterials Nature 510 2014 103 108
122. A. Leaver-Fay, M. Tyka, S.M. Lewis, O.F. Lange, J. Thompson, R. Jacak, and et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules Methods Enzymol 487 2011 545 574
123. G. Spohn, C. Schori, I. Keller, K. Sladko, C. Sina, R. Guler, and et al. Preclinical efficacy and safety of an anti-IL-1beta vaccine for the treatment of type 2 diabetes Mol Ther Methods Clin Dev 1 2014 14048
124. S. Phisitkul CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension Curr Opin Investig Drugs 10 2009 269 275
125. S.M. Goldinger, R. Dummer, P. Baumgaertner, D. Mihic-Probst, K. Schwarz, A. Hammann-Haenni, and et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients Eur J Immunol 42 2012 3049 3061
126. V. Yusibov, D.C. Hooper, S.V. Spitsin, N. Fleysh, R.B. Kean, T. Mikheeva, and et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine Vaccine 20 2002 3155 3164
127. R.L. Atmar, D.I. Bernstein, C.D. Harro, M.S. Al-Ibrahim, W.H. Chen, J. Ferreira, and et al. Norovirus vaccine against experimental human Norwalk Virus illness N Engl J Med 365 2011 2178 2187
128. H.S. Mason, J.M. Ball, J.J. Shi, X. Jiang, M.K. Estes, and C.J. Arntzen Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice Proc Natl Acad Sci U S A 93 1996 5335 5340
129. C.S. Brown, J.W. Van Lent, J.M. Vlak, and W.J. Spaan Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins J Virol 65 1991 2702 2706
130. U. Wiedermann, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer, and et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study Breast Cancer Res Treat 119 2010 673 683
131. F. De Bernardis, M. Amacker, S. Arancia, S. Sandini, C. Gremion, R. Zurbriggen, and et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models Vaccine 30 2012 4490 4498
132. G. Leroux-Roels, C. Maes, F. Clement, F. van Engelenburg, M. van den Dobbelsteen, M. Adler, and et al. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes PLoS One 8 2013 e55438
133. R. Mischler, and I.C. Metcalfe Inflexal V a trivalent virosome subunit influenza vaccine: production Vaccine 20 Suppl. 5 2002 B17 B23
134. D. Smith, I. Gow, R. Colebunders, I. Weller, S. Tchamouroff, J. Weber, and et al. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline HIV Med 2 2001 272 275